Holen Sie sich die Stockscreener-App
45.31
0.15%
-0.07
Handel nachbörslich:
45.31
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$45.38
Offen:
$45.68
24-Stunden-Volumen:
1.17M
Relative Volume:
0.45
Marktkapitalisierung:
$9.36B
Einnahmen:
$2.10B
Nettoeinkommen (Verlust:
$402.17M
KGV:
23.41
EPS:
1.9357
Netto-Cashflow:
$403.87M
1W Leistung:
-1.05%
1M Leistung:
+6.61%
6M Leistung:
+10.81%
1J Leistung:
-3.29%
1-Tages-Spanne:
$44.95
$45.69
1-Wochen-Bereich:
$43.65
$46.09
52-Wochen-Spanne:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
45.31 | 9.36B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
662.24 | 244.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
221.20 | 155.50B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
397.77 | 57.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
171.33 | 48.30B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.21 | 43.16B | 16.63B | 1.39B | 2.12B | 8.0674 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2026-09-09 | Fortgesetzt | UBS | Neutral |
| 2026-07-14 | Herabstufung | Berenberg | Buy → Hold |
| 2026-06-25 | Eingeleitet | Kepler | Hold |
| 2026-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-04-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen stock gains 0.39 percent after-hours to EUR 40.74 - AD HOC NEWS
Qiagen stock gets a new AI growth story from QIAGEN - AD HOC NEWS
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA): BlackRock Notifies 13.04% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Discloses BlackRock 12.90% Voting Rights - TradingView
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - Business Wire
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Qiagen NV (CEUX:QIAD) Shiller PE Ratio : (As of Oct. 03, 2026) - GuruFocus
QIAGEN N.V. (QIA): Bank of America Holds 4.95% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) AFM Discloses Bank of America Voting Rights Notice - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN jumps as new FDA clearance bolsters its syndromic-testing growth story - Quiver Quantitative
Qiagen (NYSE:QGEN) Shares Climb 7.7%What's Next? - MarketBeat
Qiagen gains on report talks with potential buyer have advanced (QGEN:NYSE) - Seeking Alpha
Qiagen N.V. (1QGEN.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel - Yahoo Finance UK
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel - TradingView
A Look at Qiagen NV (QGEN) After 3.9% Decline -- GF Value $49.92 vs Price $42.04 - GuruFocus
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
QIAGEN N.V. (QIA) Notified of Bank of America Voting Rights Filing - TradingView
QIAGEN N.V. (QIA): Bank of America Discloses 5.15% Holding - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Notes AFM Filing on Voting Rights Change - TradingView
QIAGEN N.V. (QIA): Bank of America At 5.15% Stake - TradingView
QIAGEN N.V. (QIA) Discloses BlackRock Voting Rights Notification - TradingView
QIAGEN N.V. (QIA): BlackRock Holds 12.97% Voting Rights - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Notes AFM Voting Rights Notice by BlackRock - TradingView
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel - BioBuzz
Qiagen NV (CEUX:QIAD) Cyclically Adjusted PB Ratio : (As of Sep. 29, 2026) - GuruFocus
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Preliminary Q1 2026 Qiagen NV Earnings Call Transcript - GuruFocus
Qiagen grounds drug discovery agents in curated knowledge - SiliconANGLE
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
QIAGEN says FDA cleared second QIAstat‑Dx bloodstream panel - Mugglehead Investment Magazine
A new infection test finds 13 bacteria and 18 signs of antibiotic resistance in about an hour. - Stock Titan
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51 - MarketBeat
Warren Wise decodes Qiagen’s DNA - TradingView
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.28%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):